Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib — Augusto Villanueva (2012) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib
Shared by
Josep M. Llovet
Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib
Letter
2012
English
Authors
AV
Augusto Villanueva
Josep M. Llovet
Translational Research In Hepatic Oncology
Abstract
1 min read
Second-line therapies are needed for patients with advanced hepatocellular carcinoma who progress after sorafenib. Positive signals seen with brivanib in phase II studies, reported herein, have yet to be confirmed in phase III trials. Identification of the molecular mechanisms driving sorafenib resistance should guide drug development strategies in this setting. Clin Cancer Res; 18(7); 1824–6. ©2012 AACR.
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Preprint
2023
Data from Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib
Augusto Villanueva
,
Josep M. Llovet
Preprint
2023
Data from Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib
Augusto Villanueva
,
Josep M. Llovet
Preprint
2023
Related Article from Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib
Augusto Villanueva
,
Josep M. Llovet
Preprint
2023
Related Article from Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib
Augusto Villanueva
,
Josep M. Llovet
Article
2011
Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition
Elizabeth Allen
,
Ian Walters
,
Douglas Hanahan
Discussion(0)
No comments yet. Be the first to comment.